Best Nucleoside Metabolic Inhibitor for leukemia, myelomonocytic, chronic
3 Nucleoside Metabolic Inhibitor drugs indicated for leukemia, myelomonocytic, chronic, ranked by our independent rating. The current highest-rated is azacitidine. Compare them with all treatments for leukemia, myelomonocytic, chronic or the full Nucleoside Metabolic Inhibitor class. Not medical advice — always consult a professional.
Top nucleoside metabolic inhibitor for leukemia, myelomonocytic, chronic: 1. Azacitidine · 2. Onureg · 3. Vidaza
| # | Drug | Rating | Type | Typical price | |
|---|---|---|---|---|---|
| 1 | Azacitidine | 70/100 | Prescription | — | View → |
| 2 | Onureg | Not yet rated | Prescription | — | View → |
| 3 | Vidaza | Not yet rated | Prescription |
Full ranking · 3 drugs
Frequently asked
- What is the best nucleoside metabolic inhibitor for leukemia, myelomonocytic, chronic?
- By our independent rating, azacitidine currently ranks highest among Nucleoside Metabolic Inhibitor drugs used for leukemia, myelomonocytic, chronic. Ratings are based on FDA regulatory (recall-safety) data — always consult a professional.
- Which nucleoside metabolic inhibitor drugs treat leukemia, myelomonocytic, chronic?
- pharmaranks lists 3 Nucleoside Metabolic Inhibitor products indicated for leukemia, myelomonocytic, chronic, per FDA drug-label data — each independently rated and ranked above.
- How are these ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.
